NewAmsterdam Pharma Company N.V. (NAMS)

19,21 -0,33 (-1,69%) Börsenschluss: 04:00PM EDT

NewAmsterdam Pharma Company N.V.

Gooimeer 2-35
Naarden 1411 DC
Netherlands
31 35 206 2971
https://www.newamsterdampharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 40

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Michael Harvey Davidson FACC, Facp., M.D.	CEO, President, Executive Board Member & Director	885,6k	N/A	1956
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.	Founder, Chief Scientific Officer, Member of Executive Board & Director	677,76k	N/A	1954
Mr. Mayur Amrat Somaiya	Chief Financial Officer	402,3k	N/A	1974
Ms. Juliette Audet M.B.A., M.Sc.	Chief Business Officer	45,62k	N/A	1987
Mr. Douglas F. Kling	Chief Operating Officer	N/A	N/A	1973
Ms. Louise Kooij	Chief Accounting Officer	N/A	N/A	1976
Mr. Jim Jacobson	Chief Legal Officer & Secretary	N/A	N/A	N/A
Dr. Marc Ditmarsch M.D.	Chief Development Officer	N/A	N/A	1967
Dr. Sheng Cui Ph.D.	VP & Head of Chemistry Manufacturing and Controls (CMC)	N/A	N/A	N/A
Ms. Annie Neild	VP & Head of Regulatory Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Corporate Governance

NewAmsterdam Pharma Company N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.